# Epilepsy advocacy: Why Hollywood's voice matters for patient care

Written by The Life Science Feed Editorial Team · Published 11 August 2026 · Edited by Mara Voss

> Epilepsy affects millions globally, yet it remains a condition frequently misunderstood and stigmatized. Patients often face significant barriers, not only in managing their seizures but also in navigating daily life, employment, and social interactions. The complexities extend beyond seizure control to encompass mental health, quality of life, and the persistent societal misconceptions that can isolate individuals.
>
> Addressing these challenges requires a multi-pronged approach, blending clinical advancements with robust public education and advocacy. Actor Greg Grunberg, known for his roles in television series like Heroes and Felicity, has emerged as a prominent voice in this space, leveraging his personal experience to champion critical issues in epilepsy advocacy.

**KEY TAKEAWAYS**

- The Pivot: Greg Grunberg's advocacy highlights the ongoing need to combat epilepsy stigma and improve access to comprehensive care.
- The Data: No specific trial data is presented, but the focus is on the qualitative impact of advocacy on patient experience.
- The Action: Clinicians should recognize the broader psychosocial challenges faced by patients with epilepsy and support advocacy efforts for improved resources and understanding.

Epilepsy is a chronic neurological disorder characterized by recurrent, unprovoked seizures. These seizures result from abnormal electrical activity in the brain, manifesting in a wide range of symptoms from brief staring spells to violent convulsions. The condition affects individuals of all ages, with varying etiologies including genetic predispositions, brain injury, infection, or developmental abnormalities. Despite advances in antiepileptic drugs (AEDs) and surgical interventions, a significant proportion of patients continue to experience uncontrolled seizures, leading to substantial morbidity and reduced quality of life.

The impact of epilepsy extends far beyond the physical manifestations of seizures. Patients frequently contend with cognitive impairments, mood disorders such as depression and anxiety, and a pervasive sense of uncertainty about when the next seizure might occur. This unpredictability can severely limit independence, affecting driving privileges, employment opportunities, and social participation. The societal perception of epilepsy, often rooted in historical misconceptions and fear, exacerbates these challenges, fostering an environment where stigma can be as debilitating as the seizures themselves.

## The Personal Stakes of Advocacy

Greg Grunberg's involvement in epilepsy advocacy stems from his son's diagnosis with the condition. This personal connection provides a powerful platform, allowing him to articulate the lived experience of patients and their families with authenticity. His advocacy centers on several key areas: reducing stigma, improving access to care, and fostering greater public awareness and understanding of epilepsy.

Stigma remains a formidable barrier for many individuals with epilepsy. It can lead to discrimination in schools, workplaces, and social settings, often resulting in isolation and psychological distress. Grunberg frequently speaks about the importance of open dialogue, encouraging patients and families to share their stories to demystify the condition and challenge preconceived notions. This direct approach aims to normalize epilepsy, shifting public perception from one of fear or pity to one of understanding and empathy.

## Navigating Treatment and Access Challenges

Access to appropriate medical care is another critical issue in epilepsy management. While a range of AEDs are available, finding the right treatment regimen can be a complex and lengthy process, often involving trials of multiple medications. Some patients may require specialized care, including epilepsy monitoring units, neurosurgical evaluations, or advanced neurostimulation therapies. But geographical disparities, insurance limitations, and a shortage of epilepsy specialists can impede timely and effective access to these essential services.

Grunberg emphasizes the need for comprehensive care models that address not only seizure control but also the broader psychosocial needs of patients. This includes access to mental health support, vocational counseling, and educational resources. The Oxford Handbook of Neurology provides a concise overview of these complex considerations, highlighting the multidisciplinary approach required for optimal patient outcomes. Advocacy efforts aim to influence policy makers and healthcare systems to prioritize these integrated services, ensuring that all patients, regardless of their location or socioeconomic status, can receive the care they need.

## The Role of Public Awareness and Education

Public education is fundamental to dismantling the stigma surrounding epilepsy. Many people lack basic knowledge about the condition, including how to respond to someone having a seizure. Misinformation can lead to dangerous interventions or, conversely, a failure to provide necessary assistance. Grunberg's advocacy includes initiatives to educate the general public on seizure first aid and to promote accurate information about epilepsy.

These educational campaigns are designed to empower bystanders to act confidently and safely when witnessing a seizure. Simple actions, such as protecting the person from injury and timing the seizure, can make a significant difference in patient safety and outcomes. By increasing public literacy about epilepsy, advocacy seeks to create a more supportive and inclusive society where individuals with the condition feel understood and valued.

## Addressing the Unmet Needs in Epilepsy Care

Despite significant progress in epilepsy research and treatment, substantial unmet needs persist. A considerable percentage of patients live with drug-resistant epilepsy, meaning their seizures cannot be controlled with available medications. For these individuals, alternative therapies such as surgery, vagus nerve stimulation, or responsive neurostimulation offer hope, but they are not universally effective and carry their own risks and considerations. The development of novel therapeutic targets and personalized medicine approaches remains an active area of research, but translating these advancements into widespread clinical practice takes time and sustained investment.

Beyond seizure control, the long-term consequences of epilepsy, including cognitive decline, bone health issues, and increased risk of sudden unexpected death in epilepsy (SUDEP), require ongoing attention. Advocacy groups push for greater funding for research into these areas, aiming to improve preventative strategies and long-term management. They also highlight the importance of patient registries and data collection to better understand disease trajectories and identify risk factors for adverse outcomes.

The open-label nature of many advocacy initiatives, while powerful in its directness, means that the impact is often qualitative rather than quantitative. It is difficult to measure the precise reduction in stigma or the exact improvement in access attributable solely to celebrity endorsement. Still, the visibility provided by figures like Grunberg undeniably amplifies the message, reaching audiences that traditional medical outreach might miss. The challenge lies in translating this heightened awareness into concrete policy changes and improved clinical resources.

The goal of epilepsy advocacy, as championed by Grunberg and others, is to ensure that individuals with epilepsy can live full, productive lives free from the burdens of stigma and inadequate care. This requires a sustained commitment from healthcare professionals, policymakers, and the public to foster a more informed and compassionate environment. The work is ongoing, but the collective voice of advocates provides a powerful impetus for change.

### CLINICAL IMPLICATIONS

Clinicians often focus on seizure control, which is understandable given the immediate risks, but Grunberg's advocacy reminds us that the psychosocial burden of epilepsy is equally critical. Patients are not just a collection of symptoms; they are individuals navigating a world that frequently misunderstands their condition. A prescription for an AED is only part of the solution.

We must actively screen for depression, anxiety, and social isolation in our epilepsy patients. Referring to support groups, advocating for workplace accommodations, and educating families on seizure first aid are all within our purview. The Oxford Handbook of Clinical Medicine provides a good starting point for holistic patient management, emphasizing the need to address the broader impact of chronic conditions.

The persistent stigma surrounding epilepsy means that many patients internalize shame, delaying diagnosis or avoiding necessary social interactions. Our role extends to being vocal advocates within our communities, challenging misconceptions and promoting accurate information. This collective effort can shift societal attitudes, creating a more inclusive environment for those living with epilepsy.

The goal is not just to reduce seizure frequency but to improve overall quality of life. This requires a commitment to understanding the patient's full experience, beyond the EEG readings and drug levels. Grunberg's voice helps bring that often-overlooked dimension to the forefront.

### EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

### REFERENCES

1. 1. Thijs RD, Surges R, O'Brien TJ, Sander JW. Epilepsy in adults. Lancet. 2019;393(10172):689-701. doi:10.1016/S0140-6736(18)32596-0

2. 2. Manford M. Recent advances in epilepsy. J Neurol. 2017;264(8):1811-1824. doi:10.1007/s00415-017-8394-2

3. 3. Samanta D. DEPDC5-related epilepsy: A comprehensive review. Epilepsy Behav. 2022;130:108678. doi:10.1016/j.yebeh.2022.108678

4. 4. Pong AW, Xu KJ, Klein P. Recent advances in pharmacotherapy for epilepsy. Curr Opin Neurol. 2023;36(2):77-85. doi:10.1097/WCO.0000000000001144

5. 5. Stone A, Burré J, Wayland N, Grinspan ZM. Phenylbutyrate for monogenetic epilepsy: Literature review. Epilepsy Res. 2025;217:107621. doi:10.1016/j.eplepsyres.2025.107621

6. 6. Beghi E, Giussani G, Sander JW. The natural history and prognosis of epilepsy. Epileptic Disord. 2015;17(3):243-53. doi:10.1684/epd.2015.0751